Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH

Aligos Therapeutics, Inc. announced that it has expanded its ongoing collaboration agreement with Merck to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis (NASH).